Inositol Hexaphosphate Inhibits Constitutive Activation of NF-κB in Androgen-independent Human Prostate Carcinoma DU145 Cells

Anticancer Research

Volumn 23, Issue 5 A, 2003, Pages 3855-3861

  Agarwal, Chapla ^a   Dhanalakshmi, Sivanandhan ^a   Singh, Rana P ^a   Agarwal, Rajesh ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Apoptosis; Inositol hexaphosphate; NF B; Prostate cancer

Indexed keywords

ANDROGEN; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PHYTIC ACID; PROTEIN P50; PROTEIN SUBUNIT; SYNAPTOTAGMIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; STAINING; WESTERN BLOTTING;

APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; MALE; NF-KAPPA B; PHYTIC ACID; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 0345305275     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Jemal A, Thomas A, Murray T and Thun M: Cancer statistics 2002. CA Cancer J Clin 52: 23-47, 2002.
2. Aquilina JW, Lipsky JJ and Bostwick DG: Androgen deprivation as a strategy for prostate cancer chemoprevention. J Natl Cancer Inst 89: 689-696, 1997.
3. Zi X, Grasso AW, Kung HJ and Agarwal R: A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 58: 1920-1929, 1988.
4. Agarwal R: Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60: 1051-1059, 2000.
5. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
6. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Uberall F and Klocker H: Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59: 227-233, 1999.
7. Carson JP, Kulik G and Weber MJ: Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res 59: 1449-1453, 1999.
8. Lin J, Adam RM, Santiestevan E and Freeman MR: The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 59: 2891-2897, 1999.
9. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF and Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284, 1999.
10. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN and Price BD: Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18: 7389-7394, 1999.
11. Miyamoto S and Verma IM: Rel/NF-kappa B/I kappa B story. Adv Cancer Res 66: 255-292, 1995.
12. Baeuerle PA and Baltimore D: NF-kappa B: ten years after. Cell 87: 13-20, 1996.
13. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A and Rao A: IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278: 860-866, 1997.
14. Zandi E, Chen Y and Karin M: Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science 281: 1360-1363, 1998.
15. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S and Baeuerle PA: Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 14: 2876-2883, 1995.
16. Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS Jr: NF-κB antiapoptosis: induction of TRAF1, TRAF2, c-IAP1 and c-IAP2 to suppress caspase-8-activation. Science 281: 1680-1683, 1998.
17. Wu MX, Ao Z, Prasad KV, Wu R and Schlossman SF: IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science 281: 998-1001, 1998.
18. Katiyar SK, Korman NJ, Mukhtar H and Agarwal R: Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 89: 556-566, 1997.
19. Zhao J, Wang J, Chen Y and Agarwal R: Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3′-gallate as the most effective antioxidant constituent. Carcinogenesis 20: 1737-1745, 1999.
20. Davis JN, Kucuk O and Sarkar FH: Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 35: 167-174, 1999.
21. Singh S and Aggarwal BB: Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270: 24995-25000, 1995.
22. Li Y and Sarkar FH: Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 8: 2369-2377, 2002.
23. Banerjee S, Bueso-Ramos C and Aggarwal BB: Suppression of 7,12-dimethylbenz(a) anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62: 4945-4954, 2002.
24. Dhanalakshmi S, Singh RP, Agarwal C and Agarwal R: Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 21: 1759-1767, 2002.
25. Shamsuddin AM, Elsayed AM and Ullah A: Suppression of large intestinal cancer in F344 rats by inositol hexaphosphate. Carcinogenesis 9: 577-580, 1988.
26. Shamsuddin AM and Vucenik I: Mammary tumor inhibition by IP6: a review. Anticancer Res 19: 3671-3674, 1999.
27. Vucenik I, Tantivejkul K, Zhang JS, Cole KE, Saied I and Shamsuddin AM: IP6 treatment of liver cancer. I: IP6 inhibits growth reverses transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res 18: 4083-4090, 1998.
28. Wattenberg LW: Chemoprevention of pulmonary carcinogenesis by myo-inositol. Anticancer Res 19: 3659-3661, 1999.
29. Ishikawa T, Nakatsuru Y, Zarkovic M and Shamsuddin AM: Inhibition of skin cancer by IP6 in vivo: initiation-promotion model. Anticancer Res 19: 3749-3752, 1999.
30. Vucenik I, Tomazik VJ, Fabian D and Shamsuddin AM: Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplanted and metastatic fibrosarcoma, pilot study. Cancer Lett 65: 9-13, 1992.
31. Zi X Singh RP and Agarwal R: Impairment of erbB1 receptor and fluid phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 21: 2225-2235, 2000.
32. Huang C, Ma WI, Hecht SS and Dong Z: Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3 kinase. Cancer Res 57: 2873-2878, 1997.
33. Shamsuddin AM and Yang GY: Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. Carcinogenesis 16: 1975-1979, 1995.
34. Shamsuddin AM: Metabolism and cellular functions of IP6: a review. Anticancer Res 19: 3733-3736, 1999.
35. El-Sherbiny YM, Cox MC, Ismail ZA, Shamsuddin AM and Vucenik I: G0/G1 arrest and S phase inhibition of human cancer cell lines by inositol hexaphosphate (IP6). Anticancer Res 21: 2393-2403, 2001.
36. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
37. Li Y and Sarkar FH: Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr 132: 3623-3631, 2002.
38. Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ: Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197, 2001.
39. Pilat MJ, Kamradt JM and Pienta KJ: Hormone resistance in prostate cancer. Cancer Metastasis 17: 373-381, 1998-99.
40. Wang CY, Mayo MW and Baldwin AS Jr: TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274: 784-787, 1996.
41. Wang CY, Cusack JC Jr, Liu R and Baldwin AS Jr: Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 5: 412-417, 1999.
42. Karin M and Lin A: NF-kappaB at the crossroads of life and death. Nature Imunol 3: 221-227, 2002.